InsidersTradesSigma
Follow the Aileron Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 9 December 2024 (Acquisition). Among the most active insiders: UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO. All data is accessible without an account.
Analysts rate Aileron Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
Aileron Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapies for cancer and other serious diseases. The company is listed on NASDAQ under the symbol ALRN.